The Impact of the Entry of Biosimilars: Evidence from Europe
Name
11151_2018_9630_ReferencePDF.pdf
Size
1.22 MB
Format
Adobe PDF
Checksum (MD5)
bb67a97f346364d293cc46d5063317bc
Author(s)
Scott Morton, Fiona M
Stern, Ariel D
Stern, Scott
Date Issued
April 25, 2018
Publisher
Springer US
Version
Author's final manuscript
Abstract
Abstract
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry, however only a few biosimilars have been approved in the US since 2015, thereby largely preserving biologics from competition. We analyze European markets, which have had biosimilar competition since 2006. Using our own survey, we analyze how market features and public policies predict biosimilar entry, price, and penetration, finding significant heterogeneity across countries and products. Effective buyer institutions are associated with increased biosimilar penetration. Our estimates can inform ongoing policy discussions.
MIT Department
Sloan School of Management
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s11151-018-9630-3
